Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Acadia Realty Trust | AKR | Nov 19, 2024 | 24.98 | +0.24 |
Acasti Pharma, Inc. | ACST | Nov 19, 2024 | 3.37 | 0.00 |
Accel Entertainment | ACEL | Nov 19, 2024 | 11.42 | -0.35 |
Accelerate Diagnostics | AXDX | Nov 19, 2024 | 1.75 | -2.78 |
Accenture A | ACN | Nov 19, 2024 | 353.95 | +0.33 |
Acco Brands | ACCO | Nov 19, 2024 | 5.71 | -1.04 |
Accolade | ACCD | Nov 19, 2024 | 3.49 | +3.25 |
Accuray | ARAY | Nov 19, 2024 | 1.84 | +8.24 |
Acelyrin | SLRN | Nov 19, 2024 | 4.72 | +1.51 |
Achieve Life Sciences | ACHV | Nov 19, 2024 | 4.34 | +4.33 |
Achilles Therapeutics ADR | ACHL | Nov 19, 2024 | 1.05 | 0.00 |
ACI Worldwide | ACIW | Nov 19, 2024 | 54.45 | -0.24 |
Aclarion | ACON | Nov 19, 2024 | 0.18 | +1.03 |
Aclaris Therapeutics | ACRS | Nov 19, 2024 | 4.59 | +46.18 |
ACM Research A | ACMR | Nov 19, 2024 | 18.40 | -0.27 |
Acme United | ACU | Nov 19, 2024 | 41.56 | -0.24 |
ACNB | ACNB | Nov 19, 2024 | 47.13 | +1.68 |
ACRES Commercial Realty | ACR | Nov 19, 2024 | 16.64 | +1.90 |
ACRES Commercial Realty C Pref | ACR-C | Nov 19, 2024 | 25.03 | -0.16 |
ACRES Commercial Realty D Pref | ACR-D | Nov 19, 2024 | 23.28 | -0.04 |
Acrivon Therapeutics | ACRV | Nov 19, 2024 | 6.38 | +1.75 |
Actelis Networks | ASNS | Nov 19, 2024 | 1.21 | +2.54 |
Actinium Pharmaceuticals | ATNM | Nov 19, 2024 | 1.42 | 0.00 |
Active Bear ETF | HDGE | Nov 19, 2024 | 17.68 | -0.04 |
Active U.S. Real Estate Powershares | PSR | Nov 19, 2024 | 96.70 | +0.75 |
Actuate Therapeutics | ACTU | Nov 19, 2024 | 8.90 | -0.67 |
Acuity Brands | AYI | Nov 19, 2024 | 316.95 | -2.02 |
Acumen Pharmaceuticals | ABOS | Nov 19, 2024 | 2.39 | +6.70 |
Acurx Pharmaceuticals | ACXP | Nov 19, 2024 | 1.67 | -1.76 |
Acushnet | GOLF | Nov 19, 2024 | 69.21 | +1.15 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.